Merck suspends Zilmax sales amid cattle mobility concerns

|By:, SA News Editor

Merck (MRK -0.8%) temporarily suspends sales of the beta-agonist Zilmax in the U.S.

The move comes on the heels of Tyson's (TSN -0.1%) decision to discontinue purchases of cattle which have been fed the supplement.

MRK has laid out a five-step plan to address allegations and suggestions that ZIlmax may be causing cattle to have difficulty walking.

Sales of Zilmax were $159M last year.

Eli Lilly (LLY -0.9%) markets a less potent beta-agonist called Optaflexx.